Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20818106 | 0.80 | TRPC5 (0.62) | TRPC5ALDH1A1POLB | |
| SCHEMBL20818103 | 0.80 | TRPC5 (0.62) | TRPC5ALDH1A1POLB | |
| SCHEMBL20818302 | 0.80 | TRPC5 (0.62) | TRPC5ALDH1A1POLB | |
| SCHEMBL24433293 | 0.78 | IDH1 (0.37) | TRPC5MAPTALDH1A1DCTPP1RXFP1 | |
| SCHEMBL20818169 | 0.78 | IDH1 (0.37) | TRPC5MAPTALDH1A1DCTPP1RXFP1 | |
| SCHEMBL31574251 | 0.78 | TRPC5 (0.37) | TRPC5MAPTALDH1A1DCTPP1RXFP1 | |
| SCHEMBL20831709 | 0.77 | GRM2 (0.35) | — | |
| SCHEMBL20818598 | 0.72 | TRPC5 (0.60) | TRPC5ALDH1A1POLB | |
| SCHEMBL20818333 | 0.72 | TRPC5 (0.60) | TRPC5ALDH1A1POLB | |
| SCHEMBL20818332 | 0.72 | TRPC5 (0.60) | TRPC5ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| WO-2019055966-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | TRPC5 1439/4885MAPT 26/4885ALDH1A1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.